De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers

Combining data from our and prior cohorts, ALK kinase domain mutations were uncommon events (<3% of cases) in ALK inhibitor-naïve ALK rearranged lung adenocarcinomas but their effect on intrinsic resistance to ALK inhibitors should be better evaluated.